Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Memory Lane

<< Previous

Bullboard Posts

Next >>

Post by TheBearInTheWoodson Dec 14, 2020 9:28pm

251 Views

Post# 32106211

Memory Lane

Didn't these guys run the price and then halt before the last terrible financing?

the question is financing or results?

good job to all those with free trading paper from the financing, who are able to get rid of paper at these levels before getting in on the next one with I imagine, another warrant.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale